A rare tumor launch using claims plus behavioral triggers and KOL-balanced content exceeded forecasts, attributing 60% of new ...
Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, outlines how Boehringer Ingelheim is positioning its ...
RayThera contributes multiple undisclosed-mechanism small-molecule immunology candidates positioned for broad applicability across immune-mediated indications, expanding modality diversity beyond ...
In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and ...
FDA approved Utebzi, an oral carbapenem antibiotic developed by GSK in partnership with Spero Therapeutics, for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in ...
Strategic emphasis has shifted away from Novavax-led commercialization toward enabling partners with global scale, exemplified by Sanofi’s worldwide rights to market the COVID vaccine and Pfizer’s ...
As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...
In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu ...
Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...
Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...
AMPLIFY-7P randomized 144 post-resection, radiographically NED mKRAS PDAC patients and missed the prespecified DFS primary endpoint in the intent-to-treat analysis. Landmark assessments showed ~14% ...
Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results